Figure 4.

Both mRNA and protein expression of CTAs in TFL are associated with HCC recurrence and HCC-specific survival. (A) Heatmap indicating co-expression of CTA mRNA in tumor-free liver tissue in the discovery and validation cohort. (B) Early HCC recurrence and HCC-specific survival in HCC patients by CTA mRNA expression in TFL in the discovery and validation cohort. Plus-signs indicate censored data. Cox–Mantel log-rank test. (C) Heatmap indicating co-expression of CTA protein in tumor-free liver tissue. (D) Early HCC recurrence and HCC-specific survival in HCC patients by CTA protein expression in TFL. Plus-signs indicate censored data. Cox–Mantel log-rank test. (E) Representative example of IHC staining of MAGEC2 protein expression in TFL and accompanying patient data. TMA slides were scanned by a Nanozoomer (Hamamatsu), and analyzed by NDP.view2 software (Hamamatsu).